Proposing a Generic Labeling Change Could Land FDA With More Work
This article was originally published in RPM Report
Opponents of FDA’s November proposed rule on generic labeling don’t necessarily think the the best option is to maintain the status quo – but the other option is to give FDA more responsibility.
You may also be interested in...
CMS streamlined process for enhanced payments is having an impact: seven antibiotic applications for New Technology Add-On Payment status in 2021—including one for a product that has been marketed for more than five years.
Updated guidance on its authority to mandate postmarketing studies affirms that a new power to impose requirements to look for diminished efficacy reaches beyond the opioid drug class.
Recent cases of individual designed treatments have FDA playing a bit of catch up. The concept has been on the horizon, but now “bespoke therapies” are here.